Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation

Fares, Suzan; Spiess, Katja; Olesen, Emma T. B.; Zuo, Jianmin; Jackson, Sarah; Kledal, Thomas N.; Wills, Mark R.; Rosenkilde, Mette M.

Published in:
mBio

DOI:
10.1128/mBio.01707-18

Publication date:
2019

Document license:
CC BY

Citation for published version (APA):
Fares, S., Spiess, K., Olesen, E. T. B., Zuo, J., Jackson, S., Kledal, T. N., ... Rosenkilde, M. M. (2019). Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation. mBio, 10(1), [e01707-18]. https://doi.org/10.1128/mBio.01707-18
Distinct Roles of Extracellular Domains in the Epstein-Barr Virus-Encoded BILF1 Receptor for Signaling and Major Histocompatibility Complex Class I Downregulation

Suzan Fares, Katja Spiess, Emma T. B. Olesen, Jianmin Zuo, Sarah Jackson, Thomas N. Kledal, Mark R. Wills, Mette M. Rosenkilde

Laboratory for Molecular and Translational Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Biochemistry, Copenhagen University Hospital, Copenhagen, Denmark
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Division of Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
National Veterinary Institute, Technical University of Denmark, Lyngby, Denmark

ABSTRACT The Epstein-Barr virus (EBV) BILF1 gene encodes a constitutively active G protein-coupled receptor (GPCR) that downregulates major histocompatibility complex (MHC) class I and induces signaling-dependent tumorigenesis. Different BILF1 homologs display highly conserved extracellular loops (ECLs) including the conserved cysteine residues involved in disulfide bridges present in class A GPCRs (GPCR bridge between transmembrane helix 3 [TM-3] and ECL-2) and in chemokine receptors (CKR bridge between the N terminus and ECL-3). In order to investigate the roles of the conserved residues in the receptor functions, 25 mutations were created in the extracellular domains. Luciferase reporter assays and flow cytometry were used to investigate the G protein signaling and MHC class I downregulation in HEK293 cells. We find that the cysteine residues involved in the GPCR bridge are important for both signaling and MHC class I downregulation, whereas the cysteine residues in the N terminus and ECL-3 are dispensable for signaling but important for MHC class I downregulation. Multiple conserved residues in the extracellular regions are important for the receptor-induced MHC class I downregulation, but not for signaling, indicating distinct structural requirements for these two functions. In an engineered receptor containing a binding site for Zn$^{2+}$ ions in a complex with an aromatic chelator (phenanthroline or bipyridine), a ligand-driven inhibition of both the receptor signaling and MHC class I downregulation was observed. Taken together, this suggests that distinct regions in EBV-BILF1 can be pharmacologically targeted to inhibit the signaling-mediated tumorigenesis and interfere with the MHC class I downregulation.

IMPORTANCE G protein-coupled receptors constitute the largest family of membrane proteins. As targets of >30% of the FDA-approved drugs, they are valuable for drug discovery. The receptor is composed of seven membrane-spanning helices and intracellular and extracellular domains. BILF1 is a receptor encoded by Epstein-Barr virus (EBV), which evades the host immune system by various strategies. BILF1 facilitates the virus immune evasion by downregulating MHC class I and is capable of inducing signaling-mediated tumorigenesis. BILF1 homologs from primate viruses show highly conserved extracellular domains. Here, we show that conserved residues in the extracellular domains of EBV-BILF1 are important for downregulating MHC class I and that the receptor signaling and immune evasion can be inhibited by drug-like small molecules. This suggests that BILF1 could be a target to inhibit the signaling-mediated tumorigenesis and immune evasion.

Citation Fares S, Spiess K, Olesen ETB, Zuo J, Jackson S, Kledal TN, Wills MR, Rosenkilde MM. 2019. Distinct roles of extracellular domains in the Epstein-Barr virus-encoded BILF1 receptor for signaling and major histocompatibility complex class I downregulation. mBio 10:e01707-18. https://doi.org/10.1128/mBio.01707-18.

Editor Salim Abdool Karim, University of KwaZulu-Natal
Copyright © 2019 Fares et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Address correspondence to Katja Spiess, kspiess@sund.ku.dk, or Mette M. Rosenkilde, rosenkilde@sund.ku.dk.
Received 7 August 2018
Accepted 28 November 2018
Published 15 January 2019
interfere with the MHC class I downregulation, thereby facilitating virus recognition by the immune system.

**KEYWORDS** EBV-BILF1, Epstein-Barr virus, GPCR, major histocompatibility complex, signaling, tumor immunology

**Epstein-Barr virus (EBV)** infects ~90% of adults worldwide (1–3). The virus is classified as a gamma 1 gammaherpesvirus in genus *Lymphocryptovirus* (LCV) and forms latent infection in B cells after the establishment of a balance between host immune response and virus immune evasion strategies. The virus is associated with growth-transforming activity in human B cells resulting in different types of cancers (4–6). In order to succeed in efficient immune evasion and establish a lifelong infection, EBV genes encode a number of immunoevasins, some of which target the major histocompatibility complex (MHC) class I molecules, including BGLF5 and BNLF2a. The virus is normally kept under T cell surveillance, yet the immunoevasins compromise the elimination of the EBV-transformed cells, thereby contributing to malignancies associated with EBV infection (4, 5, 7–9). Among these EBV-encoded immunoevasins is BILF1, a viral gene encoding a G protein-coupled receptor (GPCR). Several functions have been shown for herpesvirus-encoded GPCRs (vGPCRs) including chemokine scavenging, cell migration stimulation, and intracellular signaling reprogramming (2, 10). These genes are believed to be captured through molecular piracy during coevolution of the virus with the respective host (11–13).

The EBV-encoded BILF1 receptor downregulates MHC class I and induces signaling-mediated tumorigenesis both *in vitro* and *in vivo* (14–17). It signals constitutively via Gαi, where it modulates cyclic AMP (cAMP) response element (CRE) activation (18, 19). This constitutive activity is shared with other virus-encoded receptors such as US28 (human cytomegalovirus [HCMV]) and ORF74 (human herpesvirus 8 [HHV8]), both of which also induce signaling-mediated tumorigenesis (10, 13, 20–22). Unlike these vGPCRs, BILF1 has a unique immunomodulatory function, where it downregulates MHC class I surface expression (15–17), which causes marked impairment of T cell recognition (16, 17). BILF1 is a late lytic EBV protein (8). Its immunosuppressive activity increases as the lytic cycle of EBV progresses and it predominantly inhibits T cell recognition at the late phase of the virus lytic cycle (8). BILF1 expression has also been detected at low levels during latency in Burkitt’s lymphoma cell lines (23). Moreover, it has been detected in EBV-transformed B cell lines (8, 23).

Sequence alignment of 21 BILF1 homologs (15 closely related primate gamma 1 gammaherpesvirus-encoded BILF1 sequences and 6 sequences from the ungulate gammaherpesviruses) revealed a high degree of conservation among the extracellular loops (ECLs), especially ECL-2 (24). Among the conserved residues were the cysteine residues believed to be involved in the GPCR and chemokine characteristic disulfide bridge (24).

GPCRs are targets of more than 30% of marketed drugs with orphan receptors representing great opportunities in the treatment of many diseases (25). Nearly 400 small molecules are currently being investigated as active therapeutics for around 100 human GPCRs (25). Metal ion site engineering in GPCRs has been used as a tool for decades to study helical connectivity and provide knowledge about distance constraints and conformational changes in GPCRs. This strategy was first implemented in 1995, when Elling et al. (26) reported the conversion of the antagonist binding site in the human tachykinin NK1 receptor to a high-affinity metal ion binding site by substituting the antagonist binding site with histidine residues. Several studies followed using metal ion site engineering to probe putative binding pockets for small molecules in GPCRs (27–34). The BILF1 receptor does not resemble any other GPCR, and therefore, current X-ray and Cryo-EM structures are not applicable for building homology models. The metal ion site engineering in BILF1 is therefore a valuable strategy to predict a putative ligand binding pocket in the receptor. BILF1 signaling activity has been linked to tumor formation, and it was therefore suggested as a potential drug
target against virus-induced cancers through receptor signaling inhibition by small-molecule antagonists or inverse agonists (14). In the current study, we aimed to investigate the possibility of targeting the BILF1 receptor using small molecules in order to modulate both its signaling and immune evasion functions. We used different approaches to investigate sequence elements and predict helical connectivity of the receptor. On the basis of amino acid residue conservation, we created and characterized 25 EBV-BILF1 extracellular domain mutants in terms of MHC class I downregulation and signaling. We also engineered the receptor to contain a binding site for small "model" compounds, the metal ion chelators (32–34). We tested the aromatic chelators bipyridine and phenanthroline, in a complex with Zn\(^{2+}\), for their ability to modulate receptor signaling and MHC class I downregulation.

**RESULTS**

BILF1 is an immune evasion gene that modulates the immune system by downregulating MHC class I via the endocytic pathway, where MHC class I is targeted for internalization and the exocytic pathway, where it inhibits the appearance of newly synthesized MHC molecules at the cell surface (16, 17) (Fig. 1A). We have previously described a high degree of conservation among the ECLs of BILF1 receptors, especially ECL-2 (24). In order to investigate the roles of these conserved residues in the receptor-induced signaling and MHC class I downregulation, we generated 24 point mutations in the EBV-BILF1 extracellular domain and a mutant, where the first 17 residues of the receptor N terminus were deleted (Δ17-N-term) (Fig. 1B). A total of 25 EBV-BILF1 mutants were generated in the current study and investigated for surface expression, G-protein-mediated signaling, and MHC class I downregulation in HEK293 cells (Fig. 1B).

**Impact of conserved cysteine residues in extracellular receptor regions of EBV-BILF1.** The GPCR characteristic disulfide bridge (GPCR bridge) between the conserved cysteine residues of TM-3 and ECL-2 is a common structural feature among GPCRs (35). EBV-BILF1 displays two cysteine residues in position 97 (C97) at the top of transmembrane helix 3 (TM-3) and in position 174 (C174) in ECL-2 (Fig. 2A, red; Fig. 1B, black). These residues are conserved among BILF1 receptors (24) (Fig. 2A, red). We investigated the impact of these two residues on the receptor functions. To this end, both residues were mutated to alanine (C97A and C174A), and their surface expression and signaling were investigated. Both mutants showed reduced surface expression measured by surface ELISA against the N-terminally attached HA tag with expression of ~30% (C97A) and 10% (C174A) of that of wild-type (wt) EBV-BILF1 (Fig. 2B). ELISA and flow cytometry are commonly used techniques to measure the surface expression, internalization, and recycling of GPCRs (24, 36–39).

The G\textsubscript{α} signaling activity was investigated through their ability to modulate the forskolin-induced CRE. Forskolin activates adenylate cyclase (AC), which induces cAMP formation that will result in the downstream activation of CRE, which is inhibited by G\textsubscript{α} coupled receptors (EBV-BILF1 in this case). The C97A and C174A mutants could not inhibit the forskolin-induced CRE compared to wt EBV-BILF1, indicating an abolished G\textsubscript{α} signaling activity (Fig. 2C). This phenotype was confirmed by cotransfection with G\textsubscript{α}4myr in CRE-luciferase assay (see Fig. S1A in the supplemental material). G\textsubscript{α}4myr provides G\textsubscript{α} coupling/G\textsubscript{β} subunit signaling system, activating CRE through phospholipase C (PLC). In other words, the G\textsubscript{α} coupled BILF1 receptor recognizes this chimeric protein as a G\textsubscript{α} subunit, but it functions as G\textsubscript{β} subunit. Both mutants did not activate CRE in G\textsubscript{α}4myr-cotransfected HEK293 cells (Fig. S1A).

EBV-BILF1 displays two additional cysteine residues in the N terminus (C28) and ECL-3 (C258) (Fig. 2A, blue; Fig. 1B, black). These residues are conserved among BILF1 receptors (24) (Fig. 2A, blue). We investigated the roles of these two residues in receptor signaling and surface expression. The two residues were mutated to alanine. The mutants showed reduced surface expression of ~25% (C28A) and 12% (C258A) of that of wt EBV-BILF1 (Fig. 2B). However, both mutants retained a wt-like G\textsubscript{α} signaling activity (Fig. 2D), which was confirmed by the induction of CRE in G\textsubscript{α}4myr-cotransfected HEK293 cells (Fig. S1B). This suggests that low receptor expression per se...
does not result in low signaling and that these two cysteine residues are not important for the receptor signaling.

**Roles of conserved residues in extracellular BILF1 regions.** In order to investigate the roles of other BILF1 extracellular domain conserved residues (Fig. 3A) in receptor signaling and surface expression, we created 20 point mutations (Fig. 1B) located in ECL-1 (3 mutations [Fig. 1B, yellow]), ECL-2 (13 mutations [Fig. 1B, blue]), and ECL-3 (4 mutations [Fig. 1B, green]), and an N-terminal deletion (Fig. 1B, gray). These residues are marked with red boxes in Fig. 3A. Alanine was introduced in those conserved positions.
in the ECLs, and the first 17 residues of the EBV-BILF1 N terminus (Δ17-N-term) were deleted (Fig. 1B and 3A). The surface expression measured by ELISA and signaling of all these mutants are shown in Fig. 3 and Fig. S2. The mutants showed differential expression levels (Fig. 3B). In ECL-2a, L167A, R169A, and P171A mutants showed a wt-like surface expression level, whereas two mutants, mutants with N172A and R175A located in a closer proximity to the conserved cysteine (C174), showed lower expression than wt EBV-BILF1 did (Fig. 3B). The mutants with Q89A and E90A in ECL-1 and Y266A in ECL-3 also showed reduced expression. In contrast, the deletion of the N terminus residues (Δ17-N-term), removing the positive charge (K86A) in ECL-1 and substituting E176 and P178 in ECL-2b by alanine resulted in higher surface expression than that for wt EBV-BILF1 (Fig. 3B). The G_{i}\text{H} signaling activity for all the mutants was retained (Fig. 3C to G). Three mutants, Δ17-N-term, K86A, and P178A mutants, showed even...
higher activity compared to wt EBV-BILF1 at low DNA concentrations (Fig. 3C, D, and F), whereas two mutants, E90A and R169A mutants, showed reduced signaling activity compared to wt EBV-BILF1 (Fig. 3D and E). Figure 3 shows the surface expression and signaling of 12 mutants; the rest (9 mutants) are shown in Fig. S2. The G\(\gamma\)H925\(\gamma\)i1 signaling activity of the mutants displayed in Fig. 3 and Fig. S2 was confirmed by cotransfection of G\(\gamma\)H925\(\gamma\)i4myr in CRE-luciferase assay (Fig. S3).

Impaired MHC class I downregulation upon removal of the conserved residues in extracellular BILF1 regions. We then proceeded with the investigation of the MHC
class I downregulation function of the mutants displayed in Fig. 2 (4 mutants) and Fig. 3 (12 mutants) using flow cytometry (Fig. 4A). These mutants were selected based on their degree of conservation, position in the receptor, and their signaling and expression patterns. A representative experiment for MHC class I downregulation is shown in Fig. 4A, while Fig. 4B shows the values quantified from five independent experiments. Consistent with what has previously been shown (16, 17), wt EBV-BILF1 induced ~50% reduction in the cell surface level of MHC class I relative to cells transfected with empty vector (Fig. 4A and B). The cysteine mutants C97A, C174A, C28A, and C258A showed impaired MHC class I downregulation, where they reduced MHC class I surface level by ~20% (Fig. 4A and B). The Δ17-N-term, P171A, R175A, E176A, and P178A mutants induced a wt-like level of MHC class I downregulation (Fig. 4A and B). The K86A and R169A mutants induced a slightly, but reproducibly higher MHC class I downregulation than wt EBV-BILF1, where they reduced MHC class I surface level by ~60% (Fig. 4A and B). The mutants E90A and N172A resulted in ~40% reduction of MHC class I surface level (Fig. 4A and B). The Q89A, L167A, and Y266A mutants showed impaired MHC class I downregulation and reduced MHC class I surface level by only ~20% (Fig. 4A and B). These results indicate that various conserved residues at the receptor extracellular domain are important for the EBV-BILF1-induced surface MHC class I downregulation.

**MHC class I downregulation is correlated with EBV-BILF1 surface expression, but not signaling activity.** EBV-BILF1 has been suggested to physically associate with the MHC class I molecules at the cell surface with further internalization of the molecules (17). We used flow cytometry to measure the surface expression of the receptor mutants (Fig. 4C) along with the MHC class I surface level in HEK293 cells expressing different BILF1 mutants. Both the surface expression and MHC class I downregulation of the mutants were correlated with $r^2 > 0.5$ (Fig. 4D). The only mutant whose MHC class I downregulation was not correlated with its surface expression was the Δ17-N-term mutant (Fig. 4B to D). This mutant showed a wt-like level of MHC class I downregulation (Fig. 4A and B), but its surface expression measured by flow cytometry (Fig. 4C) was reduced relative to the wt. This could be because of improper folding of the N-terminally attached HA tag of the receptor mutant in the pCDNA3-IRES-nlsGFP and not pCMV-HA expression vector (see surface ELISA [Fig. 3B]). These results suggest that the receptor surface expression is important for the MHC class I downregulation function and implies a physical association between the receptor and MHC class I molecules at the cell surface as previously suggested (17).

BILF1 signaling activity, which has been shown to be related to the receptor-induced tumorigenesis (14), has not been consistently correlated with the receptor-induced MHC class I downregulation (16, 17). A possible link between these two functions was investigated in the current study. The Δ17-N-term, K86A, E90A, C97A, P171A, C174A, R175A, E176A, and P178A mutants showed correlated signaling and MHC class I downregulation functions (Fig. 4E), where Δ17-N-term, K86A, P171A, R175A, E176A, and P178A mutants retained a wt-like signaling and MHC class I downregulation functions (Fig. 4E). The E90A mutant, whose signaling activity was reduced also showed reduced MHC class I downregulation relative to the wt. Both the signaling activity and MHC class I downregulation functions of the C97A and C174A mutants were impaired (Fig. 4E). However, the C28A, Q89A, L167A, R169A, N172A, C258A, and Y266A mutants showed discordant signaling and MHC class I downregulation functions, where C28A, Q89A, L167A, C258A, and Y266A mutants that retained a wt-like signaling showed impaired MHC class I downregulation (Fig. 4E). In contrast, the R169A mutant, which showed reduced signaling activity (Fig. 3E and Fig. 4E), showed increased downregulation of MHC class I surface level by 60% compared to 50% for wt EBV-BILF1 (Fig. 4A and B). On the other hand, the N172A mutant retained a wt-like signaling and showed reduced MHC class I downregulation (Fig. 4E) relative to the wt. These results indicate that EBV-BILF1-induced MHC class I downregulation is not necessarily dependent on the signaling function of the receptor.

**EBV-BILF1-mediated functions can be inhibited by aromatic metal ion chelators.** No ligands have been identified for EBV-BILF1, whose signaling activity has been...
Flow cytometry showing MHC class I downregulation by different EBV-BILF1 mutants and its correlation with signaling and surface expression. (A) Histograms for the MHC class I downregulation by EBV-BILF1 mutants. HEK293T cells were transiently transfected with 1 μg of pcDNA3-HABILF1-IRES-nlsGFP. (Continued on next page)
linked to tumor formation (14). In order to investigate the possibility of the manipulation of the (i) receptor signaling activity or (ii) MHC class I downregulation function by small molecules, we created an artificial binding site in the receptor by introducing histidine (H) in position 105 (3.33 using the Ballesteros-Weinstein nomenclature [40]) and aspartic acid (D) in position 268 (7.50) to generate the F105H P268D double mutant EBV-BILF1 (Fig. 5A). The effects of the metal ion chelators (phenanthroline or bipyridine in a complex with Zn\(^{2+}\), referred to here as ZnPhe and ZnBip, respectively [Fig. 5B]) on the G\(_{\alpha}\)i signaling activity of the mutant compared to wt EBV-BILF1 were investigated in an inositol phosphate (IP3) accumulation assay in HEK293 cells cotransfected with G\(_{\alpha}\)i4myr. In wt EBV-BILF1, none of the ligands altered the basal activity of the receptor (Fig. 5C and D). In the F105H P268D double mutant, ZnPhe and ZnBip inhibited the basal activity with an EC\(_{50}\) of 1 and \(2\times10^{-5}\) M, respectively, indicating inverse agonism activity of the metal chelators (Fig. 5C and D). Both ligands inhibited the receptor

**FIG 4** Legend (Continued)

(solid black line) or empty pcDNA-IRES-nlsGFP vector (broken black line). Forty-eight hours posttransfection, the cells were harvested and analyzed by flow cytometry. The isotype control staining is shown in gray. The cells were gated at high GFP and high HA expression. (B) Bar charts showing the MHC class I downregulation by the EBV-BILF1 mutants shown in Fig. 4A, normalized to the mean anti-MHC class I fluorescence index of the empty vector. (C) Surface expression level measured by mean anti-HA fluorescence index and normalized to the vector (0%) and wild-type (WT) BILF1 (100%). (D) Correlation between the EBV-BILF1 receptor surface expression and MHC class I surface level. (E) Signaling and MHC class I downregulation activity depicted in pairs. The black bars show the signaling activity of 2.5 ng DNA concentration normalized to the vector (100%) and wt BILF1 (0%). The red bars show the MHC class I downregulation normalized as in panel B. Error bars represent SEM from three independent experiments analyzed by the paired Student t test. Statistical significance is indicated as follows: *\(, \ P < 0.05\); **\(, \ P < 0.01\); ***\(, \ P < 0.001\); ns, not significant.

**FIG 5** Effects of Zn\(^{2+}\) chelators on the signaling activity and expression of wt EBV-BILF1 and the F105H P268D double mutant EBV-BILF1. (A) Wheel diagram for EBV-BILF1 showing the F105H P268D double mutant. (B) Structure of phenanthroline (Phe) or bipyridine (Bip) in a complex with Zn\(^{2+}\) (ZnPhe and ZnBip). (C and D) IP3 accumulation in HEK293 cells cotransfected with wt pcDNA3-HABILF1-IRES-nlsGFP (closed circles) or the F105H P268D double mutant EBV-BILF1 (open circles) and G\(_{\alpha}\)i4myr, in the presence of ZnPhe (C) or ZnBip (D). The data in panels C and D were normalized to zero and maximum IP3 accumulation after background subtraction. (E and F) Surface expression level measured by mean anti-HA fluorescence index of wt BILF1 (black bars) or F105H P268D mutant (open bars) in the presence of ZnPhe (E) or ZnBip (F). The data in panels E and F were normalized to the values in the absence of the metal chelator. Error bars represent SEM from three independent experiments analyzed by the unpaired Student t test. Statistical significance is indicated as follows: *\(, \ P < 0.05\); **\(, \ P < 0.01\); ***\(, \ P < 0.001\); ns, not significant.
activity to a submaximal level (∼30%), and the level of activity depended on complex formation between Zn$^{2+}$ and the aromatic chelators as shown in Fig. S4, where no difference was observed between the signaling activity of the wt and F105H P268D double mutant EBV-BILF1 by ZnCl$_2$. Moreover, both ZnPhe and ZnBip increased the F105H P268D double mutant EBV-BILF1 surface expression by 40% and 30%, respectively, at the highest concentration of the metal chelator (Fig. 5E and F), whereas the effect on wt EBV-BILF1 expression was modest for ZnBip (15% at 10 μM) and absent for ZnPhe (Fig. 5E and F).

The effects of the chelators were further extended to the MHC class I downregulation function of the F105H P268D double mutant EBV-BILF1 compared to wt EBV-BILF1 (Fig. 6), where different concentrations (1, 10, and 100 μM) of the ligands were assessed. Both ligands slightly inhibited the MHC class I downregulation function of wt BILF1 (Fig. 6A and B) with ∼10% higher (from 40% to 50%) MHC class I surface level relative to that in the absence of ligands (Fig. 6B). The ligands inhibited the MHC class I downregulation function of the F105H P268D double mutant EBV-BILF1 (Fig. 6C and D) with ∼15% higher (from 60% to 75%) MHC class I surface expression relative to the level in the absence of ligands (Fig. 6D).

**DISCUSSION**

GPCRs possess highly diverse extracellular domains responsible for binding diverse ligands and more conserved transmembrane and intracellular domains responsible for signal transduction and binding/activating G protein and arrestins (41, 42). Interestingly, BILF1 receptors of different gammaherpesviruses display a high degree of conservation among the ECLs, a level of conservation that exceeds that of the TM region (24). In this study, we aimed to investigate the roles of the conserved residues in the EBV-BILF1 extracellular domain in relation to both receptor-mediated signaling and MHC class I downregulation, given the high degree of conservation and general
involvement of the extracellular receptor domains in ligand binding. We also investigated the susceptibility of EBV-BILF1 signaling and MHC class I downregulation functions to inhibition by small-molecule ligands. Doing this we are providing the first evidence that EBV-BILF1 is a promising drug target for interference with BILF1/MHC class I interaction facilitating antigen presentation of MHC class I/peptide targets to T cells, which would facilitate virus recognition.

**Disulfide bridges, constitutive signaling, and MHC class I downregulation.** Disulfide bridges in the GPCR extracellular domain are important for maintained receptor structure and function (33, 43, 44). The disulfide bridge between TM-3 and ECL-2 is a common structural feature among class A GPCRs and present in about 90% of the receptors (44, 45). Several studies have shown that a disruption of this bridge results in impaired ligand binding and reduced ligand-dependent signaling (33, 43, 44, 46, 47). In addition, disrupting this bridge disables 90% of the receptors from reaching the cell surface (33, 48). We obtained similar results, where mutating the conserved cysteine residues in TM-3 and ECL-2 (possibly involved in GPCR bridge) resulted in reduced cell surface expression and impaired receptor signaling. We also find that these residues are essential for EBV-BILF1-induced MHC class I downregulation. These observations imply that EBV-BILF1 shares this structural feature with the rest of class A GPCRs and that this bridge is important for the structure and function of the receptor.

The extra disulfide bridge displayed by chemokine receptors (CKR bridge) provides extra receptor constraints and regulates receptor function (33, 43, 49). Here, we show that the cysteine residues possibly involved in a CKR-like bridge formation are dispensable for EBV-BILF1-mediated G protein-coupled receptor (GPCR) signaling, whereas both residues are important for receptor-induced MHC class I downregulation. In addition, we found that both residues were important for maintained receptor cell surface expression. These results imply that EBV-BILF1 displays the CKR bridge and that this bridge stabilizes the receptor structure important for MHC class I downregulation and surface expression, but not signaling.

**Importance of the extracellular domain in EBV-BILF1-mediated functions.** In 2011, a study by Zuo et al. (16) identified important domains involved in BILF1-induced MHC class I downregulation; they showed that the DRY-like EKT signaling motif at the bottom of TM-3 is important for enhanced endocytosis, while the deletion of the receptor C-terminal domain resulted in impaired lysosomal degradation of MHC class I molecules. The high degree of conservation among BILF1 extracellular domains (24) makes it compelling to presume a preserved function, which could be maintaining (i) the high basal receptor activity, (ii) ligand binding, and/or (iii) interaction with MHC class I molecules. We therefore created different EBV-BILF1 extracellular domain mutants and investigated their ability to mediate signaling activity and reduce the surface level of MHC class I. Most of the mutants retained a wt-like signaling activity, which implies that this function is dependent on the intracellular region of the receptor, as previously reported for BILF1 (50) and other GPCRs (41, 42). In contrast, removing the conserved residues in the receptor extracellular domain resulted in an impaired MHC class I downregulation function of EBV-BILF1. The reduced surface expression of these mutants (Fig. 5C) indicates that the conserved residues at the extracellular domain maintain a receptor structure important for the interaction with MHC class I at the cell surface.

Our results suggest that EBV-BILF1 ECLs are directly or indirectly involved in the interaction with MHC class I molecules. Intriguingly, in contrast to the impact of Cys28 (in the N terminus) on the receptor immune modulation, deleting the first 17 residues of the EBV-BILF1 N terminus did not affect receptor signaling or MHC class I downregulation.

**Correlation between BILF1-induced signaling and MHC class I downregulation.** The link between BILF1 signaling and MHC class I downregulation function has not been consistently described (16, 17). It has been shown that the signaling-deficient K122A BILF1 mutant retained the ability to downregulate the MHC class I surface expression level (17). This mutant, which has disrupted EKT (DRY-like) signaling motif and showed impaired NF-κB signaling properties, could reduce MHC class I surface
levels to an extent similar to that of the wt receptor (17). It was therefore suggested that these functions are not critically related. Afterwards, it was shown that the K122A mutant could not mediate MHC class I internalization, and it was therefore suggested that the EKT motif is necessary for MHC class I-enhanced internalization through a mechanism that is probably independent of the receptor signaling activity (16). This goes in line with our findings, where we show that MHC class I downregulation and signaling activities are not necessarily dependent. Combined with previous studies (16, 17), our observations imply that the molecular mechanisms of BILF1 function(s) are complex and that further investigation of the relationship between BILF1 signaling and MHC class I downregulation properties is warranted.

**EBV-BILF1 as a drug target.** Metal ion site engineering has traditionally been used to predict the helical connectivity of GPCRs. This has been first described for the tachyklin NK1 receptor by the introduction of histidine in the non-peptide-binding site (26) and later for others (27–34). The same strategy has been implemented to describe tachykininNK1receptorbytheintroductionofhistidineinthenon-peptide-bindingsite to predict the helical connectivity of GPCRs. This has been first described for the density receptor ligand binding pocket (30).

The fact that EBV-BILF1 does not resemble any of the aforementioned receptors makes the receptor probe for such compounds challenging. Nevertheless, we successfully created an artificial binding site in EBV-BILF1 through double mutant engineering between TM-3 and TM-7. Our results raise the enticing prospect of exploiting the receptor extracellular domains (including the outer transmembrane domain) to inhibit receptor signaling and interfere with receptor/MHC class I interaction.

**MATERIALS AND METHODS**

**Cell lines and culture and transfection conditions.** Dulbecco’s modified Eagle’s medium (DMEM) purchased from Invitrogen, Germany, containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Pen-Strep), was used to grow HEK293 cells at 37°C and 10% CO₂. Transient transfection of HEK293 cells was performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions and with CaPO₄ (51).

**Vector constructs and receptor expression.** EBV-BILF1 was cloned into the pCMV-HA vector (Clontech). The expression plasmid pCDNA3-HABILF1-GFP and control empty vector pCDNA3-IRES-nlsGFP have been described previously (16, 17). The EBV-BILF1 mutants were generated by QuikChange PCR using high-fidelity Pfu DNA polymerase. The constructs were verified by restriction digestion and sequence analysis.

**Antibodies.** For enzyme-linked immunosorbent assay (ELISA) experiments, anti-hemagglutinin monoclonal antibodies (anti-HA MAbs) (anti-H11, clone 16812, mouse; HISS Diagnostics, Germany) and goat anti-mouse horseradish peroxidase-conjugated antibody purchased from Dianova, Denmark, were used. For flow cytometry, phycoerythrin (PE)-conjugated MAb, clone W6/32, (BioLegend, UK) and Alexa Fluor 647-conjugated anti-HA (Cell Signaling, UK) were used. The antibodies were diluted according to the manufacturer’s instructions.

**Recombinant G protein plasmid (Gq, Gq, or Gq, a chimeric G subunit in which 6 amino acid residues at the N terminus were deleted, a myristoylation motif was created at the N terminus, and the G subunit C-terminal residues replaced the corresponding residues in the C subunit (52). The receptor recognizes Gq, as Gq, and gives Gq, readout (52).**

**Metal ion chelators.** The aromatic chelators, bipyridine (Bip) or phenanthroline (Phe) were made in a complex with Zn²⁺. ZnCl₂ was mixed with either 2,2’-bipyridine or 1,10-phenanthroline (Sigma-Aldrich, USA) in the 1:2 ratio as previously described (32, 33).

**ELISA to measure cell surface expression.** The receptor cell surface expression was confirmed by ELISA conducted as described previously (24). Briefly, HEK293 cells were seeded in 96-well plates at a density of 2 × 10⁶ cells/well 24 h prior to transient transfection with N-terminal HA-tagged receptor cloned in the pCMV vector (15 ng). One day after the cells were seeded, the cells were fixed in 4% paraformaldehyde, blocked in PBS containing bovine serum albumin (BSA) at room temperature (RT). The cells were then incubated with the primary antibody for 1 h at RT, while shaking. This was followed by a washing step and incubation with the secondary antibody for 1 h at RT, while shaking. The activity was detected by 3,3’-5,5’-tetramethyl benzidine substrate (Kem-En-Tec, Denmark) and the reaction was stopped with H₂SO₄. The optical density (OD) was measured at 450 nm.

**cAMP response element (CRE) reporter assay.** HEK293 cells were transiently transfected 24 h after the cells were seeded at 2 × 10⁵ cells/well, with increasing amounts of the receptor/empty vector DNA, both with 25 ng/well of pFR-Luc transactivator plasmid and 6 ng/well of pFA2-CRE transreporter plasmid (Stratagene, USA) and 30 ng/well Gq, plasmid DNA (kindly provided by Evi Kostenis, University of Bonn). A concentration range of 0.5 ng to 10 ng of the receptor and empty expression vector DNA was used. For forskolin stimulation, no Gq, was added. The cells were treated with 15 μM forskolin...
Inositol trisphosphate (IP3) accumulation. The assay was performed as described previously (24, S1). Briefly, HEK293 cells were transfected with 5 μg of BILF1 or empty vector DNA and 5 μg of Gctermpr. One day after transfection, the cells were seeded in a 96-well plate at 35,000 cells/well in the presence of 4 μCi of myo-[3H]inositol. One day after the cells were seeded, the cells were incubated with different concentrations of metal ion chelators in 0.1 ml Hanks’ balanced salt solution (Invitrogen, UK) supplemented with 10 mM LiCl at 37°C for 90min. The cells were then treated as described previously (24) and measured in a top counter. Briefly, the cells were incubated in formic acid (10 mM) on ice for 30 min. The extract was transferred to a 96-well plate and incubated with YSi poly-D-lysine-coated beads (PerkinElmer, USA) diluted 1:8 while shaking at maximum speed. The radiation was measured in a Top-Counter.

Flow cytometry to analyze surface MHC class I molecules and receptors. PE-labeled W6/32 antibodies or a PE-labeled isotype control MAb were used to determine the levels of total MHC class I at HEK293T cell surface. The cells were seeded in 24-well plate 24 h prior to transient transfection with 1 μg/well of the N-terminal HA-tagged BILF1 inserted in the pcDNA3-ires-nlsGFP expression vector. Forty-eight hours after transfection, the cells were harvested and stained with anti-MHC class I and anti-HA antibody (detecting the surface level of BILF1). Zombie Red dye (BioLegend, UK) was used to stain for the live/dead (LD) cells. When the metal ion chelators were used, they were added at different concentrations at 24 h posttransfection. The samples were analyzed on a BD Accuri C6 instrument. The data were analyzed using FlowJo (TreeStar) and BD Accuri C6 software.

Data analysis and statistics. The data were analyzed with GraphPad Prism, FlowJo (TreeStar), and BD Accuri C6 software.

ACKNOWLEDGMENTS
This study was funded by the Faculty of Health and Medical Sciences, The NovoNordisk Foundation, A. P. Møller Foundation, and European Research Council. K.S. was funded by a postdoc grant from the Danish Council for Independent Research. S.F. designed the research study, conducted the experiments, analyzed the data, and wrote the manuscript. K.S. designed the research study, revised the manuscript, and contributed to data analysis. E.T.B.O. and S.J. contributed to the experimental work and data analysis. J.Z. and T.N.K. contributed to the research study. M.R.W. designed the research study, conducted the experiments, analyzed the data, and wrote the manuscript. M.M.R. designed the research study, analyzed the data, and wrote the manuscript. All authors commented on and approved the final manuscript.

We thank Maibritt Sigvardt Baggesen for skillful technical assistance.

We declare that we have no conflicts of interest with the contents of this article.

REFERENCES
1. Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ. 2015. Immune evasion by Epstein-Barr virus. Curr Top Microbiol Immunol 391:355–381. https://doi.org/10.1007/978-3-319-22834-1_12.
2. Arfelt KN, Fares S, Rosenkilde MM. 2015. EBV, the human host, and the 7TM receptors: defense or offense? Prog Mol Biol Transl Sci 129:395–427. https://doi.org/10.1016/BSE.PMBST.2014.10.011.
3. Li H, Hu J, Luo X, Bode AM, Dong Z, Cao Y. 2018. Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies. Cancer Sci 109:2101–2108. https://doi.org/10.1111/cas.13634.
4. Hislop AD, Taylor GS, Sauce D, Richardson AB. 2007. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25:587–617. https://doi.org/10.1146/annurev.immunol.25.022216.141553.
5. Becker Y, Tabor E, Asher Y. 1988. Differential expression of Epstein-Barr virus (EBV) genes BBRF3, BILF1, and BMRF2 in EBV-transformed lymphoblastoid lines from ataxia-telangiectasia patients. Leukemia 2:785–1915.
6. Nakayama T, Fujisawa R, Izawa D, Hishima K, Takada K, Yoshie O. 2002. Human B cells immortalized with Epstein-Barr virus upregulate CCR6 and CCR10 and downregulate CXCRI4 and CXCRI5. J Virol 76:3072–3077. https://doi.org/10.1128/JVI.76.6.3072-3077.2002.
7. Ehlin-Henriksson B, Liang W, Cagigi A, Mowafi F, Klein G, Nilsson A. 2009. Changes in chemokines and chemokine receptor expression on tonsillar B cells upon Epstein-Barr virus infection. Immunology 127:549–557. https://doi.org/10.1111/j.1365-2567.2008.03029.x.
8. Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD, Rowe M. 2014. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle. PLoS Pathog 10:e1004322. https://doi.org/10.1371/journal.ppat.1004322.
9. Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R. 2012. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog 8:e1002704. https://doi.org/10.1371/journal.ppat.1002704.
10. Rosendal-Gilke MM, Waldhoer M, Luttichau HR, Schwartz TW. 2001. Virally encoded TM7 receptors. Oncogene 20:1582–1593. https://doi.org/10.1038/sj.onc.1201491.

11. Rosendal-Gilke MM, Kledal TN. 2006. Targeting herpesvirus reliance of the chemokine system. Curr Drug Targets 7:103–118.

12. Holst PJ, Rosendal-Gilke MM, Mantra D, Chen SC, Wielkowiski MT, Holst B, Cifre F, Lipp M, Schwartz TW, Lira SA. 2001. Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J Clin Invest 108:1789–1796. https://doi.org/10.1172/JCI17622.

13. Spiess K, Jeppesen MG, Malmgaard-Clausen M, Krzywkoz K, Kledal TN, Rosendal-Gilke MM. 2017. Novel chemokine-based immunomodulins for potent and selective targeting of cytomegalovirus infected cells. J Immunol Res 2017:4069260. https://doi.org/10.1155/2017/4069260.

14. Lyngaa R, Norregaard K, Kristensen M, Kubele V, Rosendal-Gilke MM, Kledal TN. 2010. Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling. Oncogene 29:4386–4398. https://doi.org/10.1038/onc.2010.173.

15. Griffin BD, Gram AM, Mulder A, Van Leeuwen D, Claas FH, Wang F, Ressing ME, Wiertz EJ, Thirstrup K, Holst B, Schwartz TW. 1999. Natural agonist enhancement in melanocortin MC1 and MC4 receptors. J Biol Chem 274:47662–47670. https://doi.org/10.1074/jbc.M202103200.

16. Rosendal-Gilke MM, Lucibello M, Holst B, Schwartz TW. 1998. Natural agonist enhancing bis-His-zinc-site in transmembrane segment V of the tachykinin NK3 receptor. FEBS Lett 439:35–40.

17. Rosendal-Gilke MM, Andersen MB, Nygaard R, Frimurer TM, Schwartz TW. 2007. Activation of the CXCR3 chemokine receptor through anchoring of a small molecule chelator ligand between TM-III, -IV, and -V. Mol Pharmacol 71:930–941. https://doi.org/10.1124/mol.106.030031.

18. Rosendal-Gilke MM, Kledal TN, Brauner-Osborne H, Schwartz TW. 1999. Agonists and inverse agonists for the herpesvirus B-encoding constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem 274:956–961.

19. Thiele S, Steen A, Jensen PC, Mokrosinski J, Frimurer TM, Rosendal-Gilke MM. 2011. Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. J Biol Chem 286:37543–37554. https://doi.org/10.1074/jbc.M111.243808.

20. Barington L, Rummel PC, Luckmann M, Pihl H, Larsen O, Daugvilaite V, Johnsen AH, Frimurer TM, Karsholj S, Rosendal-Gilke MM. 2016. Role of conserved disulfide bridges and aromatic residues in extracellular loop 2 of chemokine receptor CCR8 for chemokine and small molecule binding. J Biol Chem 291:16208–16220. https://doi.org/10.1074/jbc.M116.740183.

21. Karsholj S, Amarandi RM, Larsen O, Daugvilaite V, Steen A, Brvar M, Pui A, Frimurer TM, Ulven T, Rosendal-Gilke MM. 2016. Molecular mechanism of action for allosteric modulators and agonists in CC-chemokine receptor 5 (CCR5). J Biol Chem 291:26860–26874. https://doi.org/10.1074/jbc.M116.740183.

22. Falczewski K, Kubasaki T, Hori T, Behnike MA, Cotohima H, Fox BA, Le Trott J, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. 2000. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739–745.

23. Grundmann M, Merten N, Malpacci D, Inoue A, Preis P, Simon K, Ruttiger N, Ziegler N, Benkel T, Schmitt NK, Ishida S, Muller I, Reher R, Kawakami K, Inoue A, Rick U, Kuhl T, Imhof D, Aoki J, Konig GM, Hoffmann C, Gomez J, Wess J, Kostenis E. 2018. Lack of beta-arrestin signaling in the absence of active G protein signaling. Nat Commun 9:341. https://doi.org/10.1038/s41467-017-02661-3.

24. Liesbcher I, Schon J, Petersen SC, Fischer L, Auerbach N, Demberg LM, Mogha A, Coster M, Simon KU, Rothmund S, Monk KR, Schoneberg T. 2014. A tethered agonist within the ectodomain activates the adhesion G protein-coupled receptors GPR126 and GPR133. Cell 156:2018–2026. https://doi.org/10.1016/j.celrep.2014.11.036.

25. Fares S, Faes S, Sparre-Ulrich AH, Hjorth J, Hjorth GM, Gasbjerg LS, Molleskov-Jensen AS, Bønden-Jensen T, Rosendal-Gilke MM. 2017. Signaling via G proteins mediates tumorigenic effects of GPR87. Cell Signal 30:9–18. https://doi.org/10.1016/j.cellsig.2016.11.009.

26. Ballesteros JA, Weinstein H. 1995. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors, p 366–428. In Selffon SC (ed), Receptor molecular biology. Academic Press, New York, NY.

27. Katrich V, Cherezov V, Stevens RC. 2012. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci 33:17–27. https://doi.org/10.1016/j.tips.2011.09.003.

28. Katrich V, Cherezov V, Stevens RC. 2013. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 53:531–556. https://doi.org/10.1146/annurev-pharmaco-031211-135923.

29. Rummel PC, Thiele S, Hansen LS, Petersen TP, Sparre-Ulrich AH, Ulven T, Rosendal-Gilke MM. 2013. Extracellular disulfide bridges serve different purposes in two homologous chemokine receptors, CCR1 and CCR5. Mol Pharmacol 84:335–345. https://doi.org/10.1124/mol.112.071178.

30. Peeters MC, van Westen GJ, Li Q, Uzerman AP. 2011. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol Sci 32:35–42. https://doi.org/10.1016/j.tips.2010.10.001.
ponents of a conserved disulfide bond in rhodopsin, affects the light-activated metarhodopsin II state. Proc Natl Acad Sci USA 91:4029–4033.

47. Perlman JH, Wang W, Nussenzveig DR, Gershengorn MC. 1995. A disulfide bond between conserved extracellular cysteines in the thyrotropin-releasing hormone receptor is critical for binding. J Biol Chem 270:24682–24685. https://doi.org/10.1074/jbc.270.42.24682.

48. Chabot DJ, Zhang PF, Quinnan GV, Broder CC. 1999. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. J Virol 73:6598–6609.

49. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katriitch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC. 2010. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066–1071. https://doi.org/10.1126/science.1194396.

50. Zhang J, He S, Wang Y, Brulois K, Lan K, Jung JU, Feng P. 2015. Herpesviral G protein-coupled receptors activate NFAT to induce tumor formation via inhibiting the SERCA calcium ATPase. PLoS Pathog 11: e1004768. https://doi.org/10.1371/journal.ppat.1004768.

51. Kissow H, Hartmann B, Holst JJ, Vibly NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS. 2012. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 179:91–100. https://doi.org/10.1016/j.regpep.2012.08.016.

52. Kostenis E, Martini L, Ellis J, Waldhoer M, Heydorn A, Rosenkilde MM, Norregaard PK, Jorgensen R, Whistler JL, Milligan G. 2004. A highly conserved glycine within linker I and the extreme C terminus of G protein alpha subunits interact cooperatively in switching G protein-coupled receptor-to-effector specificity. J Pharmacol Exp Ther 313:78–87. https://doi.org/10.1124/jpet.104.080424.